{"database": "lobbying", "table": "lobbying_filings_raw", "rows": [["0a5a8bea-a3ac-4083-9e00-e5eb6d2f23c3", "Q2", 69674, "NATIONAL MULTIPLE SCLEROSIS SOCIETY", 164353, "NATIONAL MULTIPLE SCLEROSIS SOCIETY", 2024, "second_quarter", "2024-07-18T12:57:22-04:00", 41572.04, 0, 0, 0, "{\"url\": \"https://lda.senate.gov/api/v1/filings/0a5a8bea-a3ac-4083-9e00-e5eb6d2f23c3/\", \"filing_uuid\": \"0a5a8bea-a3ac-4083-9e00-e5eb6d2f23c3\", \"filing_type\": \"Q2\", \"filing_type_display\": \"2nd Quarter - Report\", \"filing_year\": 2024, \"filing_period\": \"second_quarter\", \"filing_period_display\": \"2nd Quarter (Apr 1 - June 30)\", \"filing_document_url\": \"https://lda.senate.gov/filings/public/filing/0a5a8bea-a3ac-4083-9e00-e5eb6d2f23c3/print/\", \"filing_document_content_type\": \"text/html\", \"income\": null, \"expenses\": \"41572.04\", \"expenses_method\": \"A\", \"expenses_method_display\": \"A\", \"posted_by_name\": \"Bryant Robinson\", \"dt_posted\": \"2024-07-18T12:57:22-04:00\", \"termination_date\": null, \"registrant_country\": \"United States of America\", \"registrant_ppb_country\": null, \"registrant_address_1\": \"One M Street, SE\", \"registrant_address_2\": \"Suite 510\", \"registrant_different_address\": false, \"registrant_city\": \"WASHINGTON\", \"registrant_state\": \"DC\", \"registrant_zip\": \"20003\", \"registrant\": {\"id\": 69674, \"url\": \"https://lda.senate.gov/api/v1/registrants/69674/\", \"house_registrant_id\": 35789, \"name\": \"NATIONAL MULTIPLE SCLEROSIS SOCIETY\", \"description\": null, \"address_1\": \"1100 NEW YORK AVENUE, NW, #440 E\", \"address_2\": null, \"address_3\": null, \"address_4\": null, \"city\": \"WASHINGTON\", \"state\": \"DC\", \"state_display\": \"District of Columbia\", \"zip\": \"20005\", \"country\": \"US\", \"country_display\": \"United States of America\", \"ppb_country\": \"US\", \"ppb_country_display\": \"United States of America\", \"contact_name\": \"BRYANT ROBINSON\", \"contact_telephone\": \"+1 978-500-8654\", \"dt_updated\": \"2026-03-05T11:23:59.447538-05:00\"}, \"client\": {\"id\": 164353, \"url\": \"https://lda.senate.gov/api/v1/clients/164353/\", \"client_id\": 12, \"name\": \"NATIONAL MULTIPLE SCLEROSIS SOCIETY\", \"general_description\": null, \"client_government_entity\": false, \"client_self_select\": true, \"state\": \"DC\", \"state_display\": \"District of Columbia\", \"country\": \"US\", \"country_display\": \"United States of America\", \"ppb_state\": \"DC\", \"ppb_state_display\": \"District of Columbia\", \"ppb_country\": \"US\", \"ppb_country_display\": \"United States of America\", \"effective_date\": \"2007-08-10\"}, \"lobbying_activities\": [{\"general_issue_code\": \"BUD\", \"general_issue_code_display\": \"Budget/Appropriations\", \"description\": \"Supporting the following funding levels in FY25 appropriations bills: LHHS- $500 million for the Agency for Healthcare Research and Quality, $11.5 billion for the Centers for Disease Control and Prevention (inclusive of $5 million for the National Neurological Conditions Surveillance System), $20 million for the Lifespan Respite Care Program, Robust support for Medicare and Medicaid and protection of Medicaid's current financing structure, $51.3 billion for the National Institutes of Health, and at least $ 53.85 billion for the Indian Health Service. DoD- $20 million for the MS Research Program and increased baseline funding of at least 5% plus inflation for the Congressionally Directed Medical Research Programs. U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense - Dept of (DOD), Food & Drug Administration (FDA), Veterans Affairs - Dept of (VA), Natl Institutes of Health (NIH)\", \"foreign_entity_issues\": \"\", \"lobbyists\": [{\"lobbyist\": {\"id\": 25308, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"BARI\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"TALENTE\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 106090, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"NICOLE\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"BOSCHI\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 144348, \"prefix\": \"ms\", \"prefix_display\": \"MS.\", \"first_name\": \"NATASHA\", \"nickname\": null, \"middle_name\": \"AMARAL\", \"last_name\": \"SILVA\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": true}, {\"lobbyist\": {\"id\": 140518, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"BRYANT\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"ROBINSON\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 141339, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"STEFFANY\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"STERN\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 132, \"name\": \"Agency for Healthcare Research & Quality (AHRQ)\"}, {\"id\": 134, \"name\": \"Centers For Disease Control & Prevention (CDC)\"}, {\"id\": 136, \"name\": \"Centers For Medicare and Medicaid Services (CMS)\"}, {\"id\": 25, \"name\": \"Defense, Dept of (DOD)\"}, {\"id\": 135, \"name\": \"Food & Drug Administration (FDA)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 138, \"name\": \"Indian Health Service\"}, {\"id\": 139, \"name\": \"Natl Institutes of Health (NIH)\"}, {\"id\": 1, \"name\": \"SENATE\"}, {\"id\": 42, \"name\": \"Veterans Affairs, Dept of (VA)\"}]}, {\"general_issue_code\": \"HCR\", \"general_issue_code_display\": \"Health Issues\", \"description\": \"S.652 - Safe Step Act (Murkowski/Hassan), support passage H.R. 830 - HELP Copays Act, support passage S.935- Fair Accountability and Innovative Research Drug Pricing Act of 2023, support passage H.R. 485, Protecting Health Care For All Patients Act, oppose passage as currently written S.127, the Pharmacy Benefit Manager Transparency Act, support passage Urged HELP and House Energy and Commerce Committee to hold roundtables and advance proposals that address workforce issues within the healthcare community. S. 2333 - Pandemic and All-Hazards Preparedness and Response Act, support passage H.R. 824, Telehealth Benefit Expansion for Workers Act of 2023, oppose passage H.R. 4421, Preparing for All Hazards and Pathogens Reauthorization Act, monitor legislation H.R. 4420, Preparedness and Response Reauthorization Act, monitor legislation Committee Draft -The Primary Care and Health Workforce Expansion Act, support passage S. 1339, the Pharmacy Benefit Manager Reform Act, support passage S.127, the PBM Transparency Act of 2023, support passage S.113, The Prescription Pricing for the People Act of 2023, support passage S.2052, Protect Patient Access to Pharmacies Act H.R. 3561, the PATIENT Act of 2023, support passage H.R. 3284, Providers and Payers Compete Act, support passage H.R. 4507, Transparency in Coverage Act, support passage H.R. 4508, Hidden Fee Disclosure Act, support passage H.R. 2816, PBM Sunshine and Accountability Act, support passage S.79- Interagency Patent Coordination and Improvement Act of 2023, support passage S. 142- Preserve Access to Affordable Generics and Biosimilars Act, support passage S.148- Stop STALLING Act, support passage S.150- Affordable Prescriptions for Patients Act of 2023, support passage S.775-Increasing Transparency in Generic Drug Applications Act, monitoring S.1067-Ensuring Timely Access to Generics Act of 2023, support passage S. 2780 Medication Affordability and Patent Integrity Ac H.R. 4189, the CONNECT for Health Act, support passage H.R. 1843, the Telehealth Expansion Act, support passage H.R. 8018, the Alleviating Barriers for Caregivers Act, support passage S. 3109, the Alleviating Barriers for Caregivers Act, support passage H.R.6302, the Health Share Transparency Act of 2023 Joined together with coalition allies to offer recommendations for the 2026 Notice of Benefit and Payment Parameters (NBPP), as well as future rulemaking, to advance the goals of making healthcare accessible, adequate, and affordable. Joined together with coalition allies to advocate to the federal government, including HHS and CMS, to ensure that any revision of the cost-sharing rule related to copay accumulator adjustment policies includes clear, commonsense protections guaranteeing that copayments made by or on behalf of an enrollee are counted as payments toward their annual cost-sharing contributions.\", \"foreign_entity_issues\": \"\", \"lobbyists\": [{\"lobbyist\": {\"id\": 106090, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"NICOLE\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"BOSCHI\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": true}, {\"lobbyist\": {\"id\": 25308, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"BARI\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"TALENTE\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 144348, \"prefix\": \"ms\", \"prefix_display\": \"MS.\", \"first_name\": \"NATASHA\", \"nickname\": null, \"middle_name\": \"AMARAL\", \"last_name\": \"SILVA\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": true}, {\"lobbyist\": {\"id\": 140518, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"BRYANT\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"ROBINSON\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 141339, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"STEFFANY\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"STERN\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 134, \"name\": \"Centers For Disease Control & Prevention (CDC)\"}, {\"id\": 136, \"name\": \"Centers For Medicare and Medicaid Services (CMS)\"}, {\"id\": 135, \"name\": \"Food & Drug Administration (FDA)\"}, {\"id\": 34, \"name\": \"Health & Human Services, Dept of (HHS)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}, {\"general_issue_code\": \"MMM\", \"general_issue_code_display\": \"Medicare/Medicaid\", \"description\": \"Support legislation that would: maintaining current Medicaid funding structure and make the enhanced advance premium tax credits permanent, support limiting the use of inadequate short-term limited duration and other non-ACA compliant plans, address affordability of health insurance out-of-pocket costs by shifting the APTC benchmark from silver plans to gold plans to decrease out of pocket exposure for patients, ensuring the actuarial value of plans accurately reflect the financial risk faced by most consumers enrolled in the plan, support and expand Medicaid coverage in states that have not yet expanded. S.1967, Patients Before Middlemen Act, support passage S.2973, Modernizing and Ensuring PBM Accountability Act, support passage (awaiting bill number) S.2254, Medicare PBM Accountability Act, support passage In June, the Society provided input on prototype Medicare Prescription Payment Plan documents released by the Centers for Medicare and Medicaid Services. The Societys comments focused on suggestions to improve these documents so that all Medicare beneficiaries will be able to understand how to access this program regardless of preferred language or disability status. U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Office of Administration\", \"foreign_entity_issues\": \"\", \"lobbyists\": [{\"lobbyist\": {\"id\": 25308, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"BARI\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"TALENTE\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 106090, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"NICOLE\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"BOSCHI\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": true}, {\"lobbyist\": {\"id\": 144348, \"prefix\": \"ms\", \"prefix_display\": \"MS.\", \"first_name\": \"NATASHA\", \"nickname\": null, \"middle_name\": \"AMARAL\", \"last_name\": \"SILVA\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 141339, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"STEFFANY\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"STERN\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 140518, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"BRYANT\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"ROBINSON\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 136, \"name\": \"Centers For Medicare and Medicaid Services (CMS)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 17, \"name\": \"Office of Administration\"}, {\"id\": 1, \"name\": \"SENATE\"}]}, {\"general_issue_code\": \"MED\", \"general_issue_code_display\": \"Medical/Disease Research/Clinical Labs\", \"description\": \"S.79 - Interagency Patent Coordination and Improvement Act of 2023, support passage S.113, the Prescription Pricing for the People Act of 2023,support passage S.142, the Preserve Access to Affordable Generics and Biosimilars Act, support passage S.148, the Stop Stalling Act, support passage S.150, the Affordable Prescriptions for Patients Act of 2023, support passage H.R.1114- Long COVID Recovery Now Act S.801/H.S. 1616 CARE for Long COVID Act, support passage The Biosimilar Red Tape Elimination Act, monitor legislation U.S. HOUSE OF REPRESENTATIVES, U.S. Senate, Natl Institutes of Health (NIH), Defense - Dept of (DOD), Food & Drug Administration (FDA), Veterans Affairs - Dept of (VA)\", \"foreign_entity_issues\": \"\", \"lobbyists\": [{\"lobbyist\": {\"id\": 106090, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"NICOLE\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"BOSCHI\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 144348, \"prefix\": \"ms\", \"prefix_display\": \"MS.\", \"first_name\": \"NATASHA\", \"nickname\": null, \"middle_name\": \"AMARAL\", \"last_name\": \"SILVA\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 140518, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"BRYANT\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"ROBINSON\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 25308, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"BARI\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"TALENTE\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 141339, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"STEFFANY\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"STERN\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 25, \"name\": \"Defense, Dept of (DOD)\"}, {\"id\": 135, \"name\": \"Food & Drug Administration (FDA)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 139, \"name\": \"Natl Institutes of Health (NIH)\"}, {\"id\": 1, \"name\": \"SENATE\"}, {\"id\": 42, \"name\": \"Veterans Affairs, Dept of (VA)\"}]}, {\"general_issue_code\": \"TRA\", \"general_issue_code_display\": \"Transportation\", \"description\": \"Supported the Federal Aviation Administration (FAA) Reauthorization bill, HR 3935, the Securing Growth and Robust Leadership in American Aviation Act. This reauthorization bill contained several disability-related accessibility provisions the Society advocated for to improve safety and accessibility, including: new training requirements for assisting passengers with limited mobility and properly stowing assistive devices to prevent damage. Submitted individual and signed onto coalition comments on the Federal Aviation Administration (FAA)s proposed rule on Ensuring Safe Accommodations for Air Travelers with Disabilities Using Wheelchairs. The proposed rule contains numerous provisions which look to remove barriers to air travel for people who have disabilities and asking for feedback on safe and dignified air travel.\", \"foreign_entity_issues\": \"\", \"lobbyists\": [{\"lobbyist\": {\"id\": 106090, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"NICOLE\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"BOSCHI\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 25308, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"BARI\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"TALENTE\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 144348, \"prefix\": \"ms\", \"prefix_display\": \"MS.\", \"first_name\": \"NATASHA\", \"nickname\": null, \"middle_name\": \"AMARAL\", \"last_name\": \"SILVA\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": true}, {\"lobbyist\": {\"id\": 140518, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"BRYANT\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"ROBINSON\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 141339, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"STEFFANY\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"STERN\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 172, \"name\": \"Federal Aviation Administration (FAA)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}], \"conviction_disclosures\": [], \"foreign_entities\": [], \"affiliated_organizations\": []}", "DC", "US", 35789, "DC", "DC", "US", "US", null, 0, 0, 100161, null, "normalized_name_dc_fallback", 0.8]], "columns": ["filing_uuid", "filing_type", "registrant_id", "registrant_name", "client_id", "client_name", "filing_year", "filing_period", "received_date", "amount_reported", "is_amendment", "is_no_activity", "is_termination", "raw_json", "registrant_state", "registrant_country", "registrant_house_id", "client_state", "client_ppb_state", "client_country", "client_ppb_country", "client_general_description", "client_government_entity", "affiliated_org_count", "client_entity_id", "client_government_unit_id", "client_match_method", "client_match_confidence"], "primary_keys": ["filing_uuid"], "primary_key_values": ["0a5a8bea-a3ac-4083-9e00-e5eb6d2f23c3"], "units": {}, "query_ms": 203.63697595894337, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}